New fluphenazine analogues as inhibitors of P-glycoprotein in human lymphocyte cultures

Wspolczesna Onkologia

Volumn 16, Issue 4, 2012, Pages 332-337

  Jaszczyszyn, Agata ^a   Ga̧siorowski, Kazimierz ^a   Świa̧tek, Piotr ^a   Malinka, Wiesław ^a   Cieślik Boczula, Katarzyna ^b   Petrus, Joanna ^b   Czarnik Matusewicz, Bogusława ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

Author keywords

Fluphenazine analogues; MDR; MDR modulators; P glycoprotein

Indexed keywords

FLUPHENAZINE; MULTIDRUG RESISTANCE PROTEIN; PHENOTHIAZINE DERIVATIVE;

ADHESION; ARTICLE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CELL ADHESION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG CYTOTOXICITY; DRUG STRUCTURE; HISTOGRAM; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE CULTURE; PHYSICAL CHEMISTRY; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE;

EID: 84867678400     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.30063     Document Type: Article

References (21)

1. Borowski E, Bontemps-Gracz MM, Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Polonica 2005; 52: 609-27.
2. Lenart K, Szyda A, Kiełbasiński M, Duś D, Podolak-Dawidziak M. Kliniczne skutki oporności wielolekowej w nowotworach. Onkol Prakt Klin 2005; 1: 18-26.
3. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004; 104: 1940-51.
4. Johanstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? TIBS 2000; 25: 1-6.
5. Guo X, Ma N, Wang J, et al. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 2008; 8: 375-83.
6. Paja̧k B, Orzechowski A. Overview how adenocarcinoma cancer cells avoid immune- and chemotherapy-induced apoptosis. Adv Med Sci 2006; 51: 39-45.
7. Rodriguez I, Abernethy D, Woosley RL. P-glycoprotein in clinical cardiology. Circulation 1999; 99: 472-4.
8. Ga̧siorowski K, Jaszczyszyn A. Fenotiazyny w paliatywnej terapii nowotworów. Onkol Pol 2008; 11: 167-72.
9. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006; 109: 137-61.
10. Jaszczyszyn A, Ga̧siorowski K. Mechanizmy chemoprewencyjnego działania nowo syntezowanych analogów flufenazyny. Borgis, Warszawa 2006.
11. Tugg LA, Desai D, Prendergast P, Remington G, Reed K, Zipursky RB. Relationship and side effects. Schizophrenia Res 1997; 25: 71-8.
12. Ambikanandan M, Genesh S, Aliasgar S, Shan SP. Drug delivery to the central nervous system: a review. J Pharm Sci 2003; 6: 252-73.
13. Boyum A. Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 1968; 21: 77-89.
14. Hien TT, Kim HG, Han EH, Kang KW, Jeong HG. Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-κB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res 2010; 54: 918-28.
15. Jaszczyszyn A, Ga̧siorowski K, Świa̧tek P, Malinka W. Proapoptotic activity of fluphenazine analogues after blocade sphingomyelinases in cultures of human lymphocytes. Onkol Pol 2011; 14: 54-63.
16. Łachajczyk M, Procowska A, Ślusarska P, Reczuch B, Jaszczyszyn A. Badania modelowe in vitro aktywności chemoprewencyjnej flufenazyny. Flufenazyna w chorobie nowotworowej. W: Chory przewlekle - aspekty pielȩgnacyjne, rehabilitacyjne, terapeutyczne. Rosińczuk-Tonderys J, Uchmanowicz I (red.). MedPharm Polska, Wrocław 2011; 207-18.
17. Nasiłowska B. Geny oporności na leki. Postȩpy Nauk Med 2003; 3-4: 99-105.
18. Parasrampuria DA, Lantz MV, Benet LZ. A human lymphocyte based ex vivo assay to study the effect of drugs on |P-glycoprotein function. Pharm Res 2001; 18: 39-44.
19. Li H, Yan Z, Ning W, Xiao-Juan G, Cai-Hong Z, Jin-Hua J, Fang M, Qing-Duan W. Using rhodamine 123 accumulation in CD8+ cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo. J Biomed Biotechnol 2011; 2011: 281651-7.
20. Jaszczyszyn A, Ga̧siorowski K, Świa̧tek P, Malinka W, Cieślik-Boczula K, Petrus J, Czarnik-Matusewicz B. Chemical structure of phenothiazines and their biological activity. Pharmacol Rep 2012; 64: 16-23.
21. Ford JM. Prozialeck WC, Hait WN. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharm 1989; 35: 105-15.